XML 21 R8.htm IDEA: XBRL DOCUMENT v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Mar. 29, 2025
Mar. 30, 2024
Apr. 01, 2023
Cash Flows from Operating Activities:      
Net income $ 167,679 $ 117,558 $ 115,401
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization 115,586 97,215 93,307
Amortization of fair value inventory step-up 14,956 3,347 0
Share-based compensation expense 29,636 28,332 25,583
Impairment of intangible assets 2,391 10,419 607
Gain on repurchase of convertible senior notes, net (12,600) 0 0
Gains on sales of property, plant and equipment (15,698) (1,013) (943)
Remeasurement of contingent consideration (23,022) 0 (504)
Deferred income taxes (5,219) (11,039) 4,783
Other non-cash operating activities 9,978 11,633 9,321
Change in operating assets and liabilities:      
Change in accounts receivable 6,956 (24,193) (24,421)
Change in inventories (64,704) (60,061) 30,754
Change in prepaid income taxes 226 (983) 1,688
Change in other assets and other liabilities (25,232) (34,046) (22,334)
Change in accounts payable and accrued expenses (19,208) 44,582 39,816
Net cash provided by operating activities 181,725 181,751 273,058
Cash Flows from Investing Activities:      
Capital expenditures (39,278) (38,125) (191,327)
Proceeds from divestiture and sale of assets 43,291 1,500 850
Proceeds from sale of property, plant and equipment 23,253 1,810 1,608
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment (21,112) (28,171) 81,136
Acquisitions 150,906 243,852 2,850
Other investments (17,143) (15,551) (33,205)
Net cash used in investing activities (161,895) (322,389) (143,788)
Cash Flows from Financing Activities:      
Proceeds from issuance of convertible notes 700,000 0 0
Repurchase of convertible senior notes (185,500) 0 0
Purchase of capped call related to convertible notes (88,200) 0 0
Term loan borrowings 250,000 0 280,000
Term loan redemption (262,500) 0 (280,000)
Repayment of term loan borrowings (4,688) (12,250) (9,625)
Proceeds from revolving facility 0 110,000 50,000
Payments on revolving facility (50,000) (60,000) (50,000)
Debt issuance costs (23,135) 0 (1,118)
Contingent consideration payments 0 (849) (21,593)
Proceeds from employee stock purchase plan 8,333 7,214 7,016
Cash used to net share settle employee equity awards (10,243) (5,885) 0
Share repurchases (225,000) 0 (75,000)
Other financing activities (249) (73) (44)
Net cash provided by (used in) financing activities 108,818 38,157 (100,364)
Effect of exchange rates on cash and cash equivalents (685) (3,185) (3,936)
Net Change in Cash and Cash Equivalents 127,963 (105,666) 24,970
Cash and Cash Equivalents at Beginning of Year 178,800 284,466 259,496
Cash and Cash Equivalents at End of Year 306,763 178,800 284,466
Supplemental Disclosures of Cash Flow Information:      
Interest paid 16,534 20,901 13,587
Income taxes paid $ 49,293 $ 52,706 $ 17,967